1. |
Gorst SL, Gargon E, Clarke M, et al. Choosing important healthoutcomes for comparative effectiveness research: an updated review and user survey. PLoS One, 2016, 11(1): e0146444.
|
2. |
Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider. Trials, 2012, 13: 132.
|
3. |
COMET Initiative 2016. Avaliable at: .
|
4. |
Gargon E, Gurung B, Medley N, et al. Choosing Important HealthOutcomes for Comparative Effectiveness Research: A Systematic Review. PLoS One, 2014, 9(6): e99111.
|
5. |
Sinha I, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. PLoS Med, 2011, 8(1): e1000393.
|
6. |
Moher D, Schulz KF, Simera I, et al. Guidance for developers of health research reportingguidelines. PloS Med, 2010, 7(2): e1000217.
|
7. |
Clarke M, Williamson PR. Core outcome sets and systematic reviews. Syst Rev, 2016, 5: 11.
|
8. |
Kirkham JJ, Gorst S, Altman DG, et al. COS-STAR: a reporting guideline for studies developing core outcome sets (protocol). Trials, 2015, 16: 373.
|
9. |
Schmitt J, Spuls PI, Thomas KS, et al. The Harmonising OutcomeMeasures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol, 2014, 134(4): 800-807.
|
10. |
Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trial. BMJ, 2010, 340: c869.
|
11. |
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statementfor reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and Elaboration. PLoS Med, 2009, 6(7): e1000100.
|
12. |
Schmitt J, Apfelbacher C, Spuls PI, et al. The Harmonizing OutcomeMeasures for Eczema (HOME) roadmap: A methodological framework to develop core sets of outcome measurements in dermatology. J Invest Dermatol, 2015, 135(1): 24-30.
|
13. |
Smith MA, Leeder SR, Jalaludin B, et al. The asthma health outcome indicators study. Aust N Z J Public Health, 1996, 20(1): 69-75.
|
14. |
Sinha I, Gallagher R, Williamson PR, et al. Development of a core outcome set for clinical trials inchildhood asthma: a survey of clinicians, parents, and young people. Trials, 2012, 13: 103.
|
15. |
Reddel HK, Taylor DR, Bateman ED, et al. An official AmericanThoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med, 2009, 180(1): 59-99.
|
16. |
Busse WW, Morgan WJ, Taggart V, et al. Asthma outcomes workshop: overview. J Allergy Clin Immunol, 2012, 129(3 Suppl): 1-8.
|
17. |
Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updatedguidelines for reporting parallel group randomised trials. PLoS Med, 2010, 7(3): e1000251.
|
18. |
Brookes S, Macefield R, Williamson P, et al. Three nested RCTs ofdual or single stakeholder feedback within Delphi surveys during core outcome and information setdevelopment. Trials, 2015, 16(Suppl 2): 51.
|
19. |
Committee for medicinal products for human use (CHMP) (2015). Guideline on the clinical investigation of medicinal products for the treatment of asthma.Avaliable at: .
|